指南与共识皮肤肿瘤毛发、甲与色素性疾病

癌症治疗相关甲毒性:EADV 癌症患者皮肤病学工作组见解与建议

Nail toxicities associated with cancer therapies: Insights and recommendations from the EADV task force dermatology for cancer patients.
指南 / 共识 · J Eur Acad Dermatol Venereol · 2025-09-09

EADV 癌症患者皮肤病学工作组通过叙述性综述分析癌症治疗相关甲毒性的类型、严重程度、机制与管理,采用 CTCAE 5.0 分类统一评估。甲毒性表现多样,严重程度随药物类型、剂量和治疗持续时间而异,紫杉烷类和 EGFR 抑制剂等与严重甲损伤强相关。当前管理包括局部和全身治疗、支持性甲护理和预防措施,早期识别和干预至关重要。

要点

  • 癌症治疗相关甲毒性常见但报告不足,可影响生活质量并导致治疗调整。
  • 严重程度与药物类型、剂量及治疗持续时间相关,紫杉烷类和 EGFR 抑制剂风险较高。
  • 管理包括局部/全身治疗、支持性护理和预防,早期识别和干预是关键。

核心结论

  • 甲毒性是癌症治疗常见但报告不足的不良反应,可显著影响生活质量并可能导致治疗调整或中断。
  • 早期识别和干预对有效管理甲毒性至关重要,提高医护人员和患者意识有助于及时诊治。

研究设计与样本

  • EADV 癌症患者皮肤病学工作组开展的叙述性综述,全面回顾文献以识别癌症治疗相关常见甲毒性。
  • 采用 CTCAE 5.0 分类对抗癌治疗相关甲异常进行描述和评估。

主要发现

  • 甲毒性表现多样,严重程度随药物类型、剂量和治疗持续时间而变化。
  • 紫杉烷类化疗药物和 EGFR 抑制剂等靶向治疗与严重甲损伤强相关。

关键数值与推荐

  • 采用 CTCAE 5.0 分类作为描述和评估甲异常的一致框架。
  • 管理方法包括局部和全身治疗、支持性甲护理及预防措施以减少不适和并发症。

临床怎么用

  • 临床中应提高对癌症治疗相关甲毒性的认识,早期识别和干预以减少对日常生活和整体健康的影响。
  • 根据药物类型、剂量和治疗持续时间评估甲毒性风险,并采取局部/全身治疗、支持性护理和预防措施。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Nail toxicities are a frequent yet underreported adverse effect of cancer therapies. These toxicities can significantly impact patients' quality of life and may lead to treatment modifications or interruptions. This narrative review aims to analyse the types, severity and underlying mechanisms of nail toxicities associated with cancer treatments as well as their management. A comprehensive review of literature was conducted by The EADV (European Academy of Dermatology and Venereology) Task Force Dermatology for Cancer Patients to identify the most common nail toxicities related to cancer therapies. To provide a consistent framework for describing and evaluating nail abnormalities associated with anticancer therapies, the Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0 classification was used in the analysis. Nail toxicities present in diverse forms. The severity varies based on the drug type, dosage and duration of treatment. Certain chemotherapy agents, such as taxanes and targeted therapies, including EGFR inhibitors, are strongly associated with severe nail damage. Current management approaches include topical and systemic treatments, supportive nail care and preventive measures to reduce discomfort and complications. Early recognition and intervention are crucial in managing nail toxicities effectively. Awareness among healthcare providers and patients can aid in timely diagnosis and treatment, minimizing the impact on daily activities and overall well-being.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Iorizzo M, Pampaloni F, Apalla Z, et al. Nail toxicities associated with cancer therapies: Insights and recommendations from the EADV task force dermatology for cancer patients. J Eur Acad Dermatol Venereol. 2025. PMID: 40923547. doi:10.1111/jdv.70040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。